Rapid Microbiological Methods and the PAT Initiative - Numerous new RMM systems are available to replace traditional testing methods - BioPharm International


Rapid Microbiological Methods and the PAT Initiative
Numerous new RMM systems are available to replace traditional testing methods

BioPharm International
Volume 18, Issue 12

Fatty Acid Profiles (Fatty Acid Methyl Esters [FAMEs])

Type of Technology: Cell-component-based.

Premise of Technology: Fatty acids are present in microorganisms. The fatty acid composition typically is homogeneous within different taxonomic groups. Isolates are grown on standard media and selected for testing. The testing procedure includes saponification of fatty acids, methylation, and extraction, to produce fatty acid methyl esters (FAMEs). The FAMEs are measured using gas chromatography, and the measurements are compared to a library of known organisms.7

Commercial Systems Available: Sherlock Microbial Identification System (MIDI).

Other: The methods used for growth of microorganisms (media and incubation) should be standardized. Gas chromotographs should be calibrated frequently.

Fluorescent Detection of Carbon Dioxide

Type of Technology: Growth-based.

Premise of Technology: This technology allows continuous monitoring for contamination using a fluorescent carbon dioxide system. A pH-sensitive, fluorescent CO2 sensor is poured into the bottom of each container. A series of computer algorithms assess an increased rate of change and a sustained increase in CO2 production.12

Commercial Systems Available: Bactec (Becton Dickinson and Company).

Other: Commercial formulations of all microbial growth media may not be available.

Flow Cytometry (Fluorescence)

Type of Technology: Viability-based.

Premise of Technology: Using flow cytometry, microorganisms are labeled in solution with a non-fluorescent marker. The marker is taken up into the cell and cleaved by intracellular enzymatic activity to produce a fluorescing substrate. The labeled sample is automatically injected into a quartz flow cell, which passes each microorganism individually through a laser excitation beam for detection. The staining and detection mechanisms are similar to solid-phase cytometry. Flow cytometry detects organisms in solution and not in the solid phase, allowing for non-filterable solutions to be tested. Typically, results are obtained within 1.5 to 2 hours, although the limit of detection is approximately 100 cfu per mL.

Commercial Systems Available: D-Count (AES Chemunex) and RBD3000 (AATI).

Other: Systems developed for the pharmaceutical sector range from simple manual systems with single-test capability to highly automated units with high test throughput potential.

Fluorescent Probe Detection

Type of Technology: Combination, cell-component-based, nucleic-acid-based.

Premise of Technology: Nucleic acid probes are designed to bind to specific target sites on or in cells. The probes contain a molecule that is capable of fluorescing when stimulated by an energy source such as a laser. (See Nucleic Acid Probes)

Commercial Systems Available: RBD3000 (AATI).

Other: Some systems have restrictions on the sample size allowed.

Fourier Transform Infrared Spectroscopy (FTIR)

Type of Technology: Cell-component-based.

Premise of Technology: Fourier transform infrared spectroscopy can be used to generate an infrared spectrum of microorganisms. The patterns generated are stable across taxonomic groups. The patterns are compared to a database of spectra of known microorganisms.

Commercial Systems Available: A variety of systems is commercially available.

Other: Standardization is a critical performance aspect, e.g., using isolates grown on standard media using standard incubation conditions.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here